News - Shire, Biotechnology

Filter

Current filters:

ShireBiotechnology

Popular Filters

Shire sheds Dermagraft assets for $300 million in milestone payments

Shire sheds Dermagraft assets for $300 million in milestone payments

17-01-2014

Ireland-headquartered drugmaker Shire (LSE: SHP) has agreed to sell its Dermagraft (human fibroblast-derived…

BiotechnologyDermagraftDiabetesLicensingNorthern EuropeShire

arGEN-X reaches two milestone payments in Shire deal and signs research agreement with Boehringer

13-01-2014

Belgium-based biotech firm arGEN-X has reached two important success milestones in its SIMPLE Antibody…

arGEN-XBelgiumBiotechnologyBoehringer IngelheimFinancialGeneticsLicensingRare diseasesResearchShire

Shire and Santaris extend strategic alliance

23-08-2013

Danish privately held clinical-stage biopharmaceutical company Santaris Pharma says that its long term…

BiotechnologyLicensingPharmaceuticalRare diseasesResearchSantaris PharmaShire

Acceleron and Shire not to restart ACE-031 program

03-05-2013

Privately-held US biotech firm Acceleron Pharma says that Ireland-headquartered Shire (LSE: SHP) has…

Acceleron PharmaACE-031BiotechnologyLicensingPharmaceuticalRare diseasesResearchShire

Shire acquires Premacure to expand in new therapy area

13-03-2013

In a second acquisition so far this year, Ireland-headquartered drugmaker Shire (LSE: SHP) said on Tuesday…

BiotechnologyMergers & AcquisitionsOphthalmicsPharmaceuticalPremacureRare diseasesShire

Shire to acquire Lotus Tissue Repair for undisclosed price

09-01-2013

Ireland-headquartered drugmaker Shire (LSE: SHP) said yesterday that it has signed an agreement to acquire…

BiotechnologyLotus Tissue RepairMergers & AcquisitionsPharmaceuticalRare diseasesShire

arGEN-X expands antibody deal with Shire; initiates ARGX-110 trial in cancer

08-01-2013

Netherlands and Belgium-based preclinical stage biotech firm arGEN-X, specialized in the discovery and…

arGEN-XARGX-110BiotechnologyLicensingOncologyRare diseasesResearchShire

Ethris enters SNIM modified RNA alliance with Shire

07-01-2013

German biotech firm Ethris GmbH has initiated a research based alliance focused on the development and…

BiotechnologyEthris GmbHGeneticsLicensingPharmaceuticalResearchShire

Licensing deals for Amgen/ImmunoGen and Shire/Arrowhead

20-12-2012

US biotechnology company ImmunoGen (Nasdaq), which develops anticancer therapeutics using its Targeted…

AmgenArrowhead ResearchBiotechnologyImmunoGenLicensingOncologyPharmaceuticalRare diseasesShire

Promethera raises 23.6 million euros, with backers including Shire and Boehringer

28-03-2012

Belgian cell therapy company Promethera Biosciences yesterday completed a fundraising round that generated…

BiotechnologyBoehringer IngelheimFinancialHepaStemNephrology and HepatologyPromethera BiosciencesRegulationShire

EMA approves Shire Vpriv plant in USA

23-02-2012

Ireland-headquartered biopharma firm Shire (LSE: SHP) says that the European Medicines Agency's Committee…

BiotechnologyFinancialNorth AmericaPharmaceuticalRare diseasesRegulationReplagalShireVpriv

Ongoing supply problems for Genzyme’s Cerezyme

19-09-2011

US biotech Genzyme, now a subsidiary of French drug major Sanofi (Euronext: SAN), says it will have only…

BiotechnologyCerezymeFabrazymeGenzymeMarkets & MarketingPharmaceuticalRare diseasesSanofiShire

Shire drops Dermagraft for venous leg ulcers, after Ph III failure

25-08-2011

Ireland-headquartered drugmaker Shire (LSE: SHP) says that Advanced BioHealing (ABH), the USA-based regenerative…

Advanced BioHealingBiotechnologyDermagraftDermatologicalsPharmaceuticalRegulationResearchShire

Back to top